Dr. Kanavy is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
111 E 210th St
Bronx, NY 10467Phone+1 866-633-8255Fax+1 718-944-0870
Education & Training
St Barnabas HospitalResidency, Dermatology, 2011 - 2014
NYIT College Of Osteopathic MedicineClass of 2007
Certifications & Licensure
NY State License 2008 - 2027
OH State License 2010 - 2011- AOA Board of Dermatology Dermatology
Clinical Trials
- Open-Label Extension Study of Upadacitinib in Adult Participants With Moderate to Severe Atopic Dermatitis Start of enrollment: 2020 Jan 15
Publications & Presentations
PubMed
- Hand-foot skin-like reaction associated with tacrolimus therapy in a kidney transplant patient.Anna Chen, Thomas Stringer, Maria Ajaimy, Holly Kanavy
Clinical Transplantation. 2022-07-01 - 11 citationsUltra-High-Frequency Reprogramming of Individual Long-Term Hematopoietic Stem Cells Yields Low Somatic Variant Induced Pluripotent Stem Cells.Kai Wang, Anthony K. Guzman, Zi Yan, Shouping Zhang, Michael Y. Hu
Cell Reports. 2019-03-05 - 31 citationsAcral melanocytic lesions in the United States: Prevalence, awareness, and dermoscopic patterns in skin-of-color and non-Hispanic white patientsReshmi Madankumar, Priyanka Gumaste, Kathryn J. Martires, Panta Rouhani Schaffer, Sonal Choudhary
Journal of the American Academy of Dermatology. 2016-04-01
Press Mentions
Lebrikizumab Safe, Effective Against Moderate-to-Severe Eczema in Mid-Stage TrialMarch 10th, 2020
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
